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Crystal Structure at 1.7 AÊ Resolution of VEGF
in Complex with Domain 2 of the Flt-1 Receptor
1993). Experiments with knockout mice deficient in ei-
ther receptor revealed that KDR is essential for the de-
velopment of endothelial cells, whereas Flt-1 is neces-
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sary for the organization of embryonic vasculature (FongGenentech, Inc.
et al., 1995; Shalaby et al., 1995).Department of Protein Engineering
KDR and Flt-1, togetherwith the related receptor Flt-4,South San Francisco, California 94080
constitute a subgroup of the platelet-derived growth
factor (PDGF) receptor family (Van der Greer and Hunter,
1994). Flt-1 binds VEGF in the pM range and has a
10-fold higher affinity for VEGF than KDR, while Flt-4Summary
does not bind VEGF (Davis-Smyth et al., 1996). In addi-
tion to the VEGF receptor subgroup and the PDGF aVascular endothelial growth factor (VEGF) is a homodi-
and b receptors, the PDGF receptor family includes Fmsmeric hormone that induces proliferation of endothe-
(the macrophage colony-stimulating factor receptor)lialcells through binding to thekinase domain receptor
and Kit (the stem cell factor receptor). The extracellularand the Fms-like tyrosine kinase receptor (Flt-1), the
portion of these receptors is comprised of a number ofextracellular portions of which consist of seven immu-
immunoglobulin domains, 7 for the VEGF subgroup andnoglobulin domains. We show that the second and
5 for the other members. Domain deletion studies onthird domains of Flt-1 are necessary and sufficient
Flt-1 (Davis-Smyth et al., 1996; Barleon et al., 1997; Cun-for binding VEGF with near-native affinity, and that
ningham et al., 1997), the PDGF receptors (Mahadevandomain 2 alone binds only 60-fold less tightly than
et al., 1995), and Kit (Blechman et al., 1995; Lemmon etwild-type. The crystal structure of the complex be-
al., 1997) have shown that the ligand binding functiontween VEGF and the second domain of Flt-1 shows
resides within the first three domains. Deletion experi-domain 2 in a predominantly hydrophobic interaction
ments on KDR show that only domains 2 and 3 arewith the ªpolesº of the VEGF dimer. Based on this
critical for ligand binding, and that domains 4±7 are not
structure and on mutational data, we present a model
essential for signaling (Fuh et al., submitted). In addition,
of VEGF bound to the first four domains of Flt-1. it has been suggested for Flt-1 (Barleon et al., 1997) and
Kit (Blechman et al., 1995) that domain 4 may berequired
to efficiently couple ligand binding to signal transductionIntroduction
by means of direct receptor±receptor contacts.
VEGF is a homodimeric glycoprotein encoded by aVascular endothelial growth factor (VEGF) is a mitogen
single gene that is expressed in four different isoformsthat is highly specific for vascular endothelial cells (Dvo-
(VEGF121, VEGF165, VEGF189, and VEGF206) due to differentrak et al., 1995). As a potent angiogenic factor, it is
splicing events (Houck, et al., 1991; Tischer et al., 1991),
involved in the development of the vascular system and
VEGF165 being most abundant. The three longest iso-in the differentiation of endothelial cells (Carmeliet et
forms bind heparin and are found in complex with hep-
al., 1996; Ferrara et al., 1996). Angiogenesis is not only aran sulfate±containing proteoglycans in the extracellu-
important in the physiological processes of embryogen- lar matrix (Houck et al., 1991). VEGF165 can be cleaved
esis and wound healing (Peters et al., 1993), but is also by plasmin to yield an N-terminal fragment consisting
involved in pathological processes such as tumor growth, of residues 1±110 (Keyt et al., 1996a). This domain binds
metastasis, diabetic retinopathy, and rheumatoid arthri- KDR and Flt-1 as tightly as VEGF165 in the absence of
tis (Ferrara, 1995). Antibodies against VEGF can sup- heparin, but like VEGF121 has a 100-fold decreased endo-
press tumor growth in vivo (Kim et al., 1993), indicating thelial cell mitogenic activity (Keyt et al., 1996a). The
that VEGF antagonists could have broad therapeutic three-dimensional structure of the receptor-binding do-
applications. main of VEGF (residues 8±109) showed that it is a mem-
The biological function of VEGF is mediated through ber of the cystine-knot growth factor superfamily (Sun
binding to two receptor tyrosine kinases, the kinase and Davies, 1995), with greatest similarity to PDGF
domain receptor (KDR; murine flk-1) and the Fms-like (Muller et al., 1997a, 1997b). The receptor-binding face
tyrosine kinase (Flt-1), which are localized on the cell of VEGF has been identified by mutagenesis studies
surface of various endothelial cell types (Vaisman et al., (Muller et al., 1997a), revealing that the binding epitope
1990). Studies in mice have shown that the expression for KDRcontains two ªhot spots,º each of which extends
of KDR reaches the highest levels during embryonic across the dimer interface. Charge-reversal mutagene-
sis has indicated that some of these same residues arevasculogenesis and angiogenesis (Millauer et al., 1993).
also important for VEGF binding to Flt-1 (Keyt et al.,In contrast, only low levels of mRNA for Flt-1 were found
1996b).during fetal growth and moderate levels during organo-
Here, we report the results of our domain deletiongenesis, but high levels in newborn mice (Peters et al.,
study of the extracellular portion of Flt-1, as well as the
crystal structure to 1.7 AÊ resolution of the complex be-
tween the receptor-binding domain of VEGF (VEGF8±109)*C. W. and G. F. are first authors on the structure determination
and Flt-1 domain 2 (Flt-1D2). We show that an Flt-1 con-and on the expression and domain deletion studies, respectively.
²To whom correspondence should be addressed. struct consisting of domains 2 and 3 binds to VEGF with
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Table 1. Deletion Analysis of Flt-1
Relative Kda EC50 (nM)b
VEGF8±109 MAFL1 MAFL6 MAFL8 MAFL3
Dimeric constructs
1±7-IgG 1 (12 pM) 0.23 0.70 0.25
1±5-IgG 1.0 0.35
1±4-IgG 2.6 0.43 0.31 0.89 0.41
1±3-IgG 2.2 0.58 0.44 0.67 0.30
1±2-IgG 49.0 0.36 0.33 0.61
2±3-IgG 4.5 0.38 0.46 1.33 NDc
Monomeric constructs
Domains 1±7 1.9 0.68 2.69
Domains 1±3 6.7 0.46 0.63
Domain 2 113 4.34 2.02 33.5
a Binding affinities were measured as described in the Experimental Procedures. The relative affinity was derived from averaging three
independent measurements with standard errors of 615%±25%.
b The EC50 is the half-maximally effective concentration of MAb for binding to the receptor deletion construct.
c ND, not detectable. These data define the binding epitope for MAFL3 to be domain one.
near wild-type affinity, and that domain 2 by itself binds Given the ability of the constructs of domains 1±2 and
2±3 to bind VEGF tightly, the affinity of domain 2 aloneVEGF only about 60-fold weaker than the entire extracel-
lular portion. The crystal structure of the complex is the (residues 129±229) for VEGF8±109 was tested. Nonglyco-
sylated domain 2 (Flt-1D2) was produced from E. coli andfirst example of a cystine-knot growth factor bound to
a domain of its receptor. VEGF uses its receptor-binding found to bind with an affinity of 1 nM, or about 60-fold
more weakly than the monomeric version of the entireface tobind Flt-1D2 in a predominantly hydrophobic inter-
action. Flt-1D2 has several unique features compared to ectodomain of Flt-1 (Table 1). This difference in affinity
is approximately the same as that between the IgG fu-other domains of the immunoglobulin superfamily (IgSF),
including the other domains of its own extracellular por- sions of domains 1±2 and 1±7, showing that glycosyla-
tion is not important for binding. Competition for nativetion; these features are probably conserved in the sec-
ond domain of other members of the PDGF receptor ligand between Flt-1D2 and intact receptors was demon-
strated by the ability of Flt-1D2 to inhibit VEGF165-stimu-family. We propose a model of VEGF in complex with
domains 1±4 of its receptor that may be a general exam- lated proliferation of human umbilical vein endothelial
cells with an IC50 of about 180 nM (Figure 1). This IC50ple of how receptors of the PDGF family bind their li-
gands. is 300-fold higher than the IC50 for the dimeric IgG fusion
of the entire extracellular portion, in good agreement
with the 110-fold lower binding constant (Table 1).Results
Determination of Minimal VEGF-Binding Fragments Structure Determination
Systematic carboxy-terminal deletions of theseven IgSF Crystallization of the complex between VEGF8±109 and
domains of Flt-1 were carried out to define the minimal Flt-1D2 yielded two crystal forms, diffracting to 1.7 AÊ
domain(s) sufficient for high-affinity binding to VEGF. and 2.7 AÊ , respectively (Table 2). These crystal forms
The deletion variants were first expressed in mammalian contained 1 and 2 dimeric complexes per asymmetric
cells as proteins fused to the Fc portion of IgG (Fuh et
al., submitted). The domain borders were chosen based
on homology to other IgSF members (Williams and Bar-
clay, 1988; Finnerty et al., 1993). The proper folding of
all variants was verified by their ability to bind several
anti-Flt-1 monoclonal antibodies (partly shown in Table
1), three of which entirely (MAFL6) or partially (MAFL1
and -8) block ligand binding. The deletions caused very
little change in binding to VEGF8±109, until domain 3 was
removed from the 1±3 construct, which resulted in a 20-
fold reduction in affinity (Table 1). Deletion of domain 1
did not affect binding significantly (Table 1). To test
the magnitude of possible avidity effects, monomeric
glycosylated versions were produced from IgG fusions
of domains 1±7 and 1±3 that contained an engineered
Figure 1. Inhibition of VEGF165-Induced Growth of Human Umbilicalprotease site. The monomeric constructs bound about Vein Endothelial Cells by Flt-1 Constructs
2-fold more weakly than the corresponding dimeric IgG
Cells were incubated for 24 hr with 0.2 nM VEGF165 plus increasing
fusions (Table 1). Thus, for Flt-1 the increase in affinity concentrations of Flt-1D2 (closed circles) or the dimeric IgG fusion
caused by the dimeric nature of the fusion constructs of domains 1±7 (open squares) and pulsed with 0.5 mCi of [3H]thymi-
dine for 18 hr before harvesting.is only slight.
Structure of the VEGF±Flt-1D2 Complex
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Table 2. Crystallization, Data Collection, and Refinement Statistics
Data Collection
Crystal Form A B
Resolution (AÊ ) 30-1.7 (1.76±1.70)b 30-2.7 (2.76±2.70)b
Rsym (%)a 5.2 (27.7)b 4.9 (31.1)b
Number of observations 332877 157478
Unique reflections 47047 (4520)b 24098 (1544)b
Completeness (%) 99.0 (95.8)b 99.5 (98.0)b
Refinement
Resolution (AÊ ) 20±1.7
Number of reflections 45678
Final R, Rfree (F . 0.2s) 0.199, 0.261
Number of residues 382
Number of water molecules 476
Number of non-H atoms 3566
Average B factor (AÊ 2) 31.9
Rmsd bonds (AÊ ) 0.013
Rmsd angles (8) 1.76
Rms DB for bonded atoms (AÊ 2) 3.7
a Rsym 5 S|I 2 ,I. | / S I. The summation is over all unique reflections, I is the observed intensity, and ,I. is the average intensity of symmetry-
related observations of a unique reflection.
b Numbers in parentheses refer to highest resolution shell.
unit, respectively, allowing us to make extensive use which is comparable to the rms deviation of 0.45±0.80
AÊ calculated for the four copies of free VEGF8±109. Theof noncrystallographic symmetry averaging. The high-
resolution crystal structure was refined to an R value of largest differences are observed for loop regions 42±48
and 85±89, which have also been shown to vary in free19.9% (Rfree 5 26.1%), using all reflections with F greater
than 0.2s between 20 and 1.7 AÊ resolution (Table 2). VEGF8±109 (Muller et al., 1997b).
All nonglycine residues have their main-chain torsion
angles in the ªmost favorableº or in the ªadditionally
allowedº regions (Laskowski et al., 1993) of the Rama- Structure of Bound Flt-1D2
The two copies of Flt-1D2 in the complex are very similarchandran plot. The refined model consists of residues
13±107 and 12±109 of the two VEGF8±109 monomers, and to each other (the rms difference between them is 0.4
AÊ calculated over all 94 Ca positions). As predicted on132±225 and 132±226, respectively, of the two copies
of Flt-1D2, together with 476 water molecules. the basis of sequence alignments (Finnerty et al., 1993),
Flt-1D2 is a member of the IgSF. It consists of a sandwich
formed by two b sheets, one consisting of 5 strandsStructure of VEGF8±109 as Seen in the Complex
VEGF8±109 is an antiparallel homodimer, covalently linked (ba9, bc, bc9, bf, and bg), the other of 3 (bb, bd, and be)
(Figure 2). The strands in the three-stranded sheet areby two disulfide bridges between Cys-51 and Cys-60.
It has a rather unusual shape, with a maximum elonga- rather short and consist of only 3 or 4 residues. In con-
trast, the five-stranded sheet is more substantial, andtion of about 70 AÊ and a flat central part that barely spans
15 AÊ . A segment (residues 16±24) near the N terminus of strands bf and bg are 9 and 11 residues long, respec-
tively. The crossover connection between strands beeach subunit forms helix a1, which folds on top of the
other monomer in the biologically active dimer. A highly and bf includes a single helical turn at residues 199±201.
A disulfide bond between Cys-158 and Cys-207, con-irregular four-stranded b sheet comprising strands b1,
b3, b5, and b6 (Muller et al., 1997a) forms the central necting the segment immediately following strand bb to
strand bf, is buried in the hydrophobic core.part of the molecule. Two short strands, b4 and b7, are
extensions of b3 and b6, classified separately because The most unusual featureof Flt-1D2 is the conformation
of the N-terminal segment preceding strand ba9. Insteadof an interruption of the hydrogen bonding pattern. The
connection between b1 and b3 containsa short a-helical of pairing up with neighboring strand bg and forming
what is strand ba in more standard IgSF domains, resi-segment followed by a loop and strand b2, which is hy-
drogen-bonded to strand b5. This short, three-stranded dues 137±143 bulge away from the main body of the
protein (Figure 2). This bulge is anchored at its C-termi-sheet at the end of the molecule opposite to the cystine
knot in combination with helix a1 from the other subunit nal end by strand ba9 and at its beginning by the side
chain of Phe-135, which is buried in the hydrophobicwas identified as VEGF's receptor-binding face (Muller
et al., 1997a). core (Figure 3A). Because several of the residues in this
bulge are in contact with VEGF (below), this bulge mightThe overall structure of VEGF8±109 in complex with
Flt-1D2 is identical to the previously reported structure be a consequence of complex formation; thus, the pos-
sibility exists that free Flt-1D2 adopts a more canonicalof free VEGF8±109 (Muller et al., 1997a, 1997b), and no
major conformational changes are observed on Flt-1D2 IgSF conformation.
Four distinct classes of IgSFdomains have been char-binding. The two monomers in the complex have a root-
mean-square (rms) deviation of 0.64 AÊ for 94 Ca atoms, acterized, the V, C1, C2, and I sets (Harpaz and Chothia,
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conserved among I-set members is leucine in Flt-1D2;
the smaller size of the Leu-169 side chain is compen-
sated for by other buried residues nearby.
The VEGF±Flt-1D2 Interface
The overall structure of the complex follows the internal
approximate two-fold symmetry of the VEGF dimer (Fig-
ure 4). However, the differences in crystal packing envi-
ronment between the two individual molecules do intro-
duce some differences in orientation. Superposition of
the entire complex onto itself, rotated around the local
two-fold symmetry axis, results in a rather large rms
deviation of 1.54 AÊ for 376 Ca atoms. This difference is
accounted for by small rotations of the individual Flt-
1D2 molecules with respect to the VEGF dimer, pivoted
around the interface. The two interfaces themselves are
Figure 2. Ribbon Rendering of Flt-1D2, in Two Views Related by a virtually identical, with the exception of two poorly de-
Rotation of Approximately 908 about the Vertical Axis fined residues near the C terminus of Flt-1D2. Excluding
The termini and the secondary structure elements as defined by the these two residues from the calculation, the total surface
program Procheck (Laskowski et al., 1993) are labeled; b strands buried by VEGF8±109 on Flt-1D2 is 827 AÊ 2 and 817 AÊ 2, re-
are rendered as green arrows, the helical turn as a green ribbon, spectively, for each of the two copies.
and the loop regions as gray tubes. The disulfide bond is shown in
Flt-1D2 is in contact with both subunits of the ligand.ball-and-stick rendering, with sulfur atoms colored yellow. The two
The region covered on VEGF8±109 agrees well with thepotential N-linked glycosylation sites at Asn-164 and Asn-196 are
previously proposed receptor-binding face (Muller et al.,colored blue. The VEGF binding site is located on the ªbottomº end
of the five-stranded sheet; residues in contact with VEGF in the 1997a) but includes more of the exposed surface on the
complex are colored red. A segment near the N terminus, which ªpoleº of the molecule than previously suspected (see
forms strand ba in members of the I set of the immunoglobulin Figure 5).The contact surface is divided about 65%/35%
superfamily, bulges away from the core of the domain. This figure between the two VEGF subunits. The segments of
was created using the program MOLMOL (Koradi et al., 1996).
VEGF8±109 in contact with Flt-1D2 include residues from
the N-terminal helix (16±27), the loop connecting b3 to
b4 (61±66) and strand b7 (103±106) of one monomer, as1994). The structure shows that Flt-1D2 is a distant mem-
well as residues from strand b2 (46±48) and from strandsber of the I set, despite significant differences from ca-
b5 and b6 together with the connecting turn (79±91) ofnonical I-set structures. Flt-1D2 has a strand topology the other. Flt-1D2 faces VEGF with the ªbottomº half ofthat is similar to that of I-set member telokin (Holden
its five-stranded sheet (Figure 2), a surface made up
et al., 1992) and can be superimposed on the telokin
of residues from the N-terminal bulge, strand ba9, part
structure with an rms difference of 1.4 AÊ (66 Ca atoms
of strands bg and bf, the loop connecting strands bc
within a distance cutoff of 3.0 AÊ ). Of the 20 key positions
and bc9, and the helical turn connecting strands be
in the V-frame profile that define the I set (Harpaz and and bf.
Chothia, 1994), only 14 fulfill the required criteria in Flt- Figure 5 shows a space-filling rendering of the sur-
1D2. The other 6 positions all involve residues displayed faces buried in the interface between VEGF8±109 and
from the five-stranded sheet. Two differences are found Flt-1D2. The interface is dominated by hydrophobic con-
in the so-called ªY-cornerº motif, a sequence consisting tacts, which make up almost 70% of the total buried
of residues D-x-G/A/D-x-Y-x-C (Hemmingsen et al., surface. Altogether, of 21 ligand and 26 receptor resi-
1994), at the N-terminal end of strand bf. The first aspar- dues contributing to the interface, 9 are leucine or isoleu-
tic acid is replaced conservatively by Glu-201, and the cine residues, accounting for 24% of the total buried
tyrosine residue by Leu-205. Usually, the tyrosine hy- surface. It is noteworthy that both the surface of the
droxyl group forms a hydrogen bond to the carbonyl ligand and the surface of the receptor are rather flat and
oxygen of the first residue of the motif. In Flt-1D2, this lack a predominant knob-into-hole interaction. The only
hydrogen-bonding function is fulfilled instead by Thr-222 direct polar interaction is a bidentate set of charge-
from strand bg, which is normally a key hydrophobic mediated hydrogen bonds between the side chains of
residue (Figure 3B). The overall conformation of this Arg-224 of Flt-1D2 and Asp-63 of VEGF (Figure 3C). In
region remains very similar to the standard Y-corner addition, 14 buried solvent molecules are found in the
motif; thus, this alternative set of residues constitute a interface, 7 of which bridge between the ligand and the
variation of this structural feature. Strand bg contains receptor (see Figure 3C). Three water molecules are
two other sites, which in Flt-1D2 are occupied by Tyr-220 trapped in a cavity near the center of the interface,
and Arg-224 instead of strictly hydrophobic residues. formed by Asn-62, Tyr-21, and Lys-48 of VEGF and Ile-
The side chain of Tyr-220 occupies the position taken 202, Gly-203, Thr-222, and His-223 of Flt-1D2.
by strand ba in telokin; therefore, this change may be
related to the unusual bulging N-terminal segment of Discussion
Flt-1D2. Interestingly, Arg-224 has a special function as
ligand binding determinant, because its side chain Domain 2 of Flt-1 Is Sufficient for Tight
makes intimate charge-mediated hydrogen bonding in- VEGF Binding
teractions with VEGF (Figure 3C; see below). Finally, a Dimerized forms of KDR bind about 100-fold more tightly
than their corresponding monomeric forms (Fuh et al.,buried tryptophan residue on strand bc that is strictly
Structure of the VEGF±Flt-1D2 Complex
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Figure 3. Stereo Views in Ball-and-Stick
Rendering of Structural Details
Hydrogen bonds are shown as dotted lines;
oxygen atoms are colored red, nitrogens dark
blue, and carbons gray. This figure was gen-
erated using the programs MOLSCRIPT
(Kraulis, 1991) and RASTER3D (Merrit and
Murphy, 1994).
(A) The environment of Phe-135 of Flt-1.
(B) The region in Flt-1 corresponding to the
ªY cornerº found in most Greek key barrel
proteins.
(C) A region of the interface between VEGF
(in dark gray) and Flt-1 (in light gray) around
the interaction between Asp-63 and Arg-224,
showing a chain of water molecules in the
interface.
submitted), while dimerized forms of Flt-1 bind only sensitivity limit of the assay. At any rate, monomeric
Flt-1 binds VEGF about 100-fold more tightly than mono-2-fold more tightly. The reason for the difference in avid-
ity could be that receptor±receptor interactions in dimer- meric KDR.
Our deletion analysis of Flt-1 shows that domains 2±3ized receptors would not add significantly to the binding
energy of monomeric Flt-1 constructs binding tightly to are sufficient for binding VEGF8±109 with near wild-type
affinity. Similar results were found for deletions in KDRboth poles of VEGF. Alternatively, the high affinity of
monomeric Flt-1 for VEGF could have reached the (Fuh et al., submitted). Further deletion of domain 3 of
Cell
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The discrepancy is likely due to the choice of domain
boundaries. This can now be rationalized, because the
structure shows that the previous deletions either cut
into the last b strand of the second domain or had extra
residues that presumably destabilize the overall folding.
The importance of domain 2 for biological function is
demonstrated by the observation that it contains epi-
topes for the three neutralizing antibodies and that it
can inhibit the activity of VEGF165 in a human endothelial
cell proliferation assay.
Comparison with the KDR Binding Site
Deduced from Mutagenesis Data
A comprehensive mutagenesis study of VEGF has en-
abled us to identify its receptor-binding determinants
for KDR and to define its receptor-binding face (Muller
et al., 1997a). Of the 7 VEGF residues that were found
to be of moderate to great importance for tight binding
to KDR, 5 are buried in the interface with Flt-1D2 in the
structure of the complex (Figure 5), suggesting that the
binding sites for KDR and Flt-1 are very similar. The
remaining two binding determinants for KDR are Glu-
64 and Ile-43, for which alanine substitution resulted inFigure 4. Ribbon Representation of the Complex Between VEGF8±109
and Flt-1D2 110- and 20-fold decreased affinity, respectively. These
residues are located just outside the contact region withThe two monomers of VEGF8±109 are shown in red and blue, respec-
tively; the two copies of Flt-1D2 in green. The secondary structure Flt-1D2 (see Figure 5) and form part of a groove that
elements of VEGF8±109 as well as all terminal residues are labeled. connects the ªpoleº to the ªbottomº face of VEGF. The
(A) ªBottomº view, looking up from the membrane; (B) side view, observation that the C-terminal segment of Flt-1D2 endswith the membrane below. Ribbon representation generated using
in the immediate vicinity of this groove (Figure 6A) sug-the program MOLSCRIPT (Kraulis, 1991).
gests that in the native complex, these residues may
contact the third domain of the receptor.
Flt-1, however,only causes a 20-fold decrease in affinity,
compared to a larger than 1000-fold decrease for KDR. Location of Domains 1 and 3 in the Native Complex
The second domain of Flt-1 uses the C-terminal half ofThus, the relative importance of domain 3 is different
for Flt-1 and KDR. Flt-1D2 produced from E. coli binds its five-stranded sheet to bind to the pole of the flat and
elongated VEGF dimer. This orientation places the NVEGF8±109 with an affinity similar to that of a glycosylated
construct of domains 1±2. This is consistent with previ- terminus of Flt-1D2 at a distance of 28 AÊ from VEGF8±109,
pointing away from the ligand (see Figure 4). Moreover,ous studies showing that glycosylation of Flt-1 is not
important for binding (Barleon et al., 1997). However, our domain deletion studies show that deletion of do-
main 1 only affects binding affinity by two-fold or less.these results contradict reports suggesting that domain
2 by itself is not sufficient for binding (Davis-Smyth, Therefore, we believe it is unlikely that the first domain
of Flt-1 interacts directly with the ligand in the native1996; Barleon et al., 1997; Cunningham et al., 1997).
Figure 5. Space-Filling Rendering of VEGF8±109 and Flt-1D2, in ªOpen Bookº View
(Left) Functional map of the KDR binding site on the receptor binding domain of VEGF (Muller et al., 1997a). Binding determinants are color-
coded based on the magnitude of the decrease in binding upon alanine substitution (dark red, .100-fold; orange, 50- to 100-fold; yellow, 10-
to 50-fold; light yellow, 3- to 10-fold).
(Center and Right) Buried surface between VEGF8±109 (center) and Flt-1D2 (right). Contact residues are color-coded in different shades of red,
reflecting the percentage of accessible surface buried in the interface (dark red, 75%±100%; orange, 50%±75%; yellow, 25%±50%; light
yellow, 0%±25%). The two VEGF images have been adjusted to create a wall-eyed stereo view of the surface; note the groove between
residues 64 and 43. Model generated using the program CONIC (Huang et al., 1991).
Structure of the VEGF±Flt-1D2 Complex
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Figure 7. Sequence Alignment of Domain 2 of the Members of the
PDGF Receptor Family
Secondary structure elements observed for Flt-1D2 are shown and
labeled as in Figure 2, and key I-set positions are marked by closed
circles. Homologous residues are shaded, Flt-1 residues in contact
Figure 6. Location of Other Domains of Flt-1 with VEGF are shown in red, and the two potential N-linked glycosyl-
(A) Surface rendering of VEGF8±109 with the contact regions of Flt- ation sites of Flt-1D2 are in blue. Human sequences were taken from
1D2 in tube representation, generated using the program GRASP the SwissProt Data Bank (accession numbers P17948, P35968,
(Nicholls et al., 1993) and color-coded for electrostatic potential. P35916, P09619, P16234, P07333, and P10721).
Blue and red indicate positively and negatively charged patches on
the surface of VEGF8±109, respectively; selected VEGF residues are
labeled. The C terminus of Flt-1D2 reaches toward a groove between
Glu-64 and Ile-43. Glu-64 is an important binding determinant of Using the structures of Flt-1D2 and telokin (Holden et
VEGF for binding to Flt-1 (Keyt et al., 1996b), and both of these al., 1992) as templates, we built models of the individual
residues are important for high-affinity binding of VEGF to KDR domains 1, 3, and 4 of Flt-1. We then constructed a
(Muller et al., 1997a).
dimeric model of the receptor-binding domain of VEGF(B) Model of a complex between VEGF8±109 and domains 1±4 of
in complex with domains 1±4 of Flt-1 (Figure 6B), basedFlt-1. The two VEGF subunits are colored red and blue, respectively,
on the assumptions described above. In this model,domain 2 of Flt-1 is in green, and the other domains of Flt-1 are in
different shades of gray. domain 1 points away from the ligand, the domain 2±3
linker occupies the groove in VEGF, and domain 3 is in
contact with its ªbottomº face. The likely orientation ofcomplex. If this is true, a possible function for this do-
the two copies of domain 3 places their C-terminal endsmain might be that in the absence of ligand it shields
in close proximity, suggesting direct receptor±receptorthe hydrophobic surface of domain 2, and then is dis-
contacts between domains 4 (Figure 6B). This functionplaced by VEGF upon complex formation.
of domain 4 agrees with previous proposals that it mayCompared to domain 2 alone, a construct of domains
be involved in receptor dimerization of Flt-1 (Barleon et2 and 3 binds VEGF about 20-fold tighter. This observa-
al., 1997).tion, combined with the analysis of the mutagenesis
data in light of our crystal structure, strongly suggests
that domain 3 is involved in direct contacts with the Implications for Other PDGF Receptor
Family Membersligand. In the structure of the complex, the C-terminal
three residues of Flt-1D2 are disordered, but the visible Sequence alignmentof themembers of the PDGF recep-
tor family reveals that their first four domains have manyC-terminal end extends toward a 6.5 AÊ wide groove
between the monomers, which connects the pole of of the key I-set residues, suggesting that they all belong
to the I set of the IgSF. Furthermore, many of the uniqueVEGF to its membrane-facing side (Figure 6A). The walls
of this groove are formed by the side chains of Asp-63 features of Flt-1D2 are conserved in the second domain
of the other members, suggesting that they share similarand Glu-64 on one side, and Ile-43, Ile-46, and Tyr-36
on the other, while the bottom is made of Asp-34 and structural characteristics distinct from the other do-
mains of these receptors (Figure 7). For example, theSer-30. The groove appears barely wide enough to ac-
commodate a polypeptide chain, but the residues form- characteristic core tryptophan residue of strand bc is
always a leucine in the second domain. Residue Phe-ing the walls reside on flexible regions of VEGF8±109 in
its free state (Muller et al., 1997b). Furthermore, the side 135 of Flt-1D2, anchoring the N-terminal bulge to the core
of the domain, is conserved as phenylalanine (trypto-chains of Phe-36 and Ile-46 adopt different conforma-
tions in the two copies of VEGF8±109 in our complex, phan in Fms) in domain 2 of all receptors of the PDGF
family, suggesting that the distinctive bulge of Flt-1D2suggesting an additional mechanism for widening the
groove. Based on these observations, we suggest that may be present in some of the other members as well.
In Flt-1D2, strand bb comprises only three residues andin the native complex the linker between domains 2 and
3 may occupy the groove, positioning the third domain is terminated by a Pro-Cys motif, which is conserved in
all second domains except that of Kit. The be strandin contact with the ªbottomº face of VEGF. (We believe
the reason for thedisordered C terminus of ourconstruct contains a strictly conserved Gly-191, leaving room to
accommodate the side chain of Trp-186, which is con-may be that electrostatic repulsion between the artificial
C terminus and Glu-64 and Asp-34 of VEGF prevents served as an aromatic residue in all members except
Kit. Finally, the linker region between domains 1 and 2the chain from entering the groove.)
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as an insoluble protein in E. coli. Inclusion bodies were isolated byhas a rather well-conserved consensus sequence Y-V/
passing homogenized cells in 20 mM Tris±HCl (pH 7.5), 5 mM EDTAL/I-F/Y-I/V-x-D.
through a French pressure cell and centrifuging the homogenateDomain deletion studies on the PDGF receptor (Maha-
for 15 min at 4000 3 g. The inclusion bodies were resuspended and
devan et al., 1995), on Kit (Blechman et al., 1995; Lem- the centrifugation repeated. The pellet containing primarily Flt-1D2
mon et al., 1997), and on Flt-1 (Davis-Smyth et al., 1996; was dissolved in 6 M urea, 20 mM Tris±HCl (pH 7.5), and stirred for
1±2 hr in 10 mM DTT. The protein was refolded by diluting the aboveBarleon et al., 1997) have previously indicated that do-
solution in 6 M urea to 0.05 mg/ml and dialyzing overnight againstmains 2 and 3 carry ligand-binding determinants of
2 M urea, 20 mM Tris±HCl (pH 8.0), 1 mM cysteine. The result-these receptors. We have demonstrated that these same
ing solution was further dialyzed against Tris±HCl (pH 8.0) for an-two domains of KDR (Fuh et al., submitted) and Flt-1
other 24 hr.
are necessary and sufficient for native affinity. For Flt-1 Refolded Flt-1D2 was purified to homogeneity in consecutive steps
(Barleon et al., 1997) and Kit (Blechman et al., 1995), of hydrophobic interaction (Alkyl-Sepharose, Pharmacia) and size
exclusion chromatography (S-100, Pharmacia). The purity of theligand-induced cross-linking of receptors was only ob-
protein was assessed by SDS±PAGE and mass spectrometry. Finalserved for constructs containing at least the first four
yields from refolding were about 10 mg per 50 g of cell paste, ordomains, suggesting that in the complex the two copies
about 20% of total Flt-1D2. Purified Flt-1D2 was mixed in a 2.1:1of domain 4 are close together. Taken together with our
molar ratio with VEGF8±109. The resulting complex was purified by
crystal structure, these data and the sequence similar- gel filtration chromatography (S-200, Pharmacia) and concentrated
ities discussed above suggest a common structural by ultra filtration to 7 mg/ml. The composition of the complex was
confirmed by size exclusion chromatography and reverse-phasescaffold used in the same functional manner. Thus, the
HPLC (Vydac, 214 nm).receptors of the PDGF family may all use domains 2
and 3 for ligand binding and domain 4 for direct recep-
Crystallization and Data Collectiontor±receptor contacts, in a way generally analogous to
Crystals were grown by vapor diffusion at room temperature usingour model of VEGF8±109 in complex with domains 1±4 of the hanging drop method. Crystallization buffer containing 30%
Flt-1. PEG-4000, 0.2 M ammonium sulfate, 0.02% NaN3, and 0.15 M Tris±
HCl at pH 8.5 was mixed in equal volume with protein solution (7
Experimental Procedures mg/ml, 20 mM Tris±HCl [pH 7.5]). Two different crystal forms were
found that appeared occasionally in the same drops. Both crystal
Production of Deletion Variants and of Flt-1 Domain 2 forms belonged to space group C2 with cell dimensions of a 5 81.44
Transient expression in 293 cells of the IgG fusions of Flt-1 variants AÊ , b 5 71.13 AÊ , c 5 77.86 AÊ , b 5 105.288 (form A), and a 5 124.31
and production of the monomers of Flt-1 domains 1±7 and 1±3 are AÊ , b 5 67.01 AÊ , c 5 120.84 AÊ , b 5 118.158 (form B), respectively.
described elsewhere (Fuh et al., submitted). Constructs containing These crystal forms contained 1 and 2 complexes, respectively, in
Flt-1 domains 1±5, 1±4, 1±3, 1±2, and 2±3 correspond to amino the asymmetric unit.
acids 1±558, 1±431, 1±339, 1±229, and 1±339 with 27±131 deleted, Crystals were soaked in artificial mother liquor (30% PEG-4000,
respectively. N-terminal analysis of the secreted protein, Flt-1 do- 0.2 M ammonium sulfate, 0.15 M Tris±HCl [pH 8.5]), then dipped in
mains 1±7, shows that residues 1±26 constitute the signal sequence. artificial mother liquor brought to 10% glycerol and flash-frozen in
For expression of domain 2 alone, residues 129±229 of Flt-1 were liquid nitrogen. A 1.7 AÊ data set from a form A crystal was collected
constructed in a phagemid vector under the control of an alkaline on an ADSC 1K CCD detector at the Cornell High Energy Synchro-
phosphatase promoter and stII secretion signal. tron Source on beam line A1, l 5 0.908 AÊ . For form B, data to
2.7 AÊ resolution were collected on a MAR-Research imaging plate
system using a Rigaku rotating anode generatorwith mirror-focusedBinding Assays
Receptor binding assays using [125I]VEGF165 (ICN, DuPont) and CuKa radiation. The data sets were reduced using programs DENZO
and SCALEPACK (Otwinowski, 1993) (Table 2).monoclonal antibody binding assays were done as described else-
where (Fuh et al., submitted). Briefly, receptor-IgG fusions or mono-
mers were incubated with [125I]VEGF165 and increasing concentra- Structure Determination and Refinement
tions of VEGF8±109 for 18 hr at room temperature in 100 ml of binding The structure was determined by molecular replacement and
buffer containing 0.5% bovineserum albumin, 0.05% Tween 20, 0.15 6-fold noncrystallographic symmetry averaging across the two crys-
M NaCl, and 20 mM Tris±HCl (pH 7.5). The mixture was transferred to tal forms. Using the program AMoRe (CCP4, 1994) and the high
a 96-well plate coated with anti-Fc antibody for Flt-1-IgG assays or resolution structure of the free VEGF8±109 dimer (Muller et al., 1997b)
MAFL3 for Flt-1 monomer assays and allowed to equilibrate for 15 as a search model, clear solutions were found for one dimer in the
min before washing and counting the plate. For binding assays form A cell and two independent dimers in the form B cell. The initial
with E. coli±expressed domain 2, biotinylated VEGF8±109 was used. R values for all data between 12 and 4 AÊ were 48.2% and 49.2%
Dilutions of purified Flt-1D2 were incubated with 0.5 nM of biotiny- for the A and B crystal forms, respectively. Attempts to place models
lated VEGF8±109 for 2 hr on a 96-well plate coated with an anti-VEGF of Flt-1D2 failed.
monoclonal antibody that competes with Flt-1D2 binding before add- To identify the position of the Flt-1D2 molecules, a mask with a
ing horseradish peroxidase±conjugated Streptavidin (Jackson Im- radius of 30 AÊ was created around the VEGF8±109 molecules in the A
munoResearch Lab, Inc., West Grove, PA). cell and then transferred to the B cell. After overlap removal with
program NCSMASK (CCP4, 1994) in both crystal forms, the edited
[3H]Thymidine Incorporation Assay mask was used for solvent flattening and 6-fold cross-crystal aver-
For assays with human umbilical vein endothelial cells (purchased aging with program DMMULTI (CCP4, 1994), using the symmetry
from Cell System, Kirkland, WA), cells were seeded in 96-well plates operators relating the VEGF8±109 molecules to each other. The re-
(2000 cells per well) and fasted in DMEM F12 media with 1% DFBS sulting electron density was partially interpretable for 5 of the 6
for 24 hr. VEGF165 (0.2 nM) together with increasing concentrations expected Flt-1D2 molecules and allowed building of about 60% of
of the Flt-1 variants was added in fresh fasting media, incubated the known sequence. Symmetry operators relating the resulting
for 18 hr, and pulsed with [3H]thymidine (0.5 mCi/well) for 24 hr, after fragments were optimized by rigid body refinement using the pro-
which the cells were harvested and counted. gram X-PLOR (BruÈnger et al., 1987), and the refined positions were
used to improve the mask.
The refined symmetry operators, improved mask, andphase infor-Refolding and Purification
VEGF8±109 was expressed, refolded, and purified as described mation from the VEGF8±109 molecules and the partial model of Flt-1D2
were used in a subsequent averaging procedure, resulting in greatly(Christinger et al., 1996). A construct comprising residues 129±229
of Flt-1, corresponding to the second IgSF domain, was expressed improved electron density maps. Subsequent model building and
Structure of the VEGF±Flt-1D2 Complex
703
refinement were done in crystal form A, using the programs O (Jones Vascular permeability factor/vascular endothelial growth factor, mi-
crovascular hyperpermeability, and angiogenesis. Am. J. Pathol.et al., 1991), X-PLOR (BruÈnger et al., 1987), and REFMAC (CCP4,
1994). A random set of 2275 reflections was sequestered and used 146, 1029±1039.
to monitor the free R value (BruÈ nger, 1992). Alternate cycles of Ferrara, N. (1995). The role of vascular endothelial growth factor in
refinement and model building, accompanied by addition of water pathological angiogenesis. Breast Cancer Res. Treat. 36, 127±137.
molecules, and inclusion of a solvent mask (k 5 0.39 e/AÊ 3, B 5 Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea,
65 AÊ 2), resulted in the final model with Rfree 5 26.1% and good K.S., Powell-Braxton, L., Hillan, K.J., and Moore, M.W. (1996). Het-
stereochemistry (see Table 2). Structural comparisons were done erozygous embryonic lethality induced by targeted inactivation of
using the program O, with a distance cutoff of 3.8 AÊ unless otherwise the VEGF gene. Nature 380, 439±442.
indicated.
Finnerty, H., Kelleher, K., Morris, G.E., Bean, K., Merberg, D.M., Kriz,
R., Morris, J.C., Sookdeo, H., Turner, K.J., and Wood, C.R. (1993).
Model Building Molecular cloning of murine FLT and FLT4. Oncogene 8, 2293±2298.
The 20 I-set domain fingerprint residues were identified in the se- Fong, G.-H., Rossant, J., Gertsenstein, M., and Beritman, M.L.
quences of domains 1, 3, and 4 of Flt-1, andmodels of these domains (1995). Role of the flt-1 receptor tyrosine kinase in regulating the
were built using the structures of Flt-1D2 and telokin as templates. assembly of vascular endothelium. Nature 376, 66±70.
Domains 1 and 2 were connected through an eight-residue linker.
Harpaz, Y., and Chothia, C. (1994). Many of the immunoglobulinDomain 3 was built with a bulge in its N-terminal segment like that
superfamily domains in cell adhesion molecules and surface recep-observed in domain 2; this bulge was placed in the groove of VEGF
tors belong to a new structural set which is close to that containingconnecting its pole to its ªbottomº face. This arrangement posi-
variable domains. J. Mol. Biol. 238, 528±539.
tioned the C-terminal ends of the two symmetry-related copies of
Hemmingsen, J.M., Genert, K.M., Richardson, J.S., and Richardson,domain 3 close to each other. Domain 4 was placed in intimate
D.C. (1994). The tyrosine corner: a feature of most greek key b-barrelcontact with its symmetry mate, using an eight-residue link from
proteins. Prot. Sci. 3, 1927±1937.domain 3.
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Protein Data Bank Accession Codes
The coordinates for VEGF8±109 in complex with Flt-1D2 have been
deposited in the Brookhaven Protein Data Bank under the code 1flt.
However, these coordinates will not be released until October 1998.
